Login to Your Account



Mesoblast lightens load as FDA talks allow trimming trial size

By Michael Fitzhugh
Staff Writer

Tuesday, January 12, 2016

SAN FRANCISCO – FDA support for Mesoblast Ltd.'s plan to nearly halve the size of an ongoing phase III study in chronic heart failure and alter its endpoint will make the study significantly cheaper and faster to read out, while also making it more clinically and economically meaningful, CEO Silviu Itescu told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription